Our findings highlight that disruption of SNRPD3 protein methylation using PRMT5 inhibitors is a promising novel therapeutic target for the treatment of high-risk neuroblastoma, particularly given the observed SNRPD3- and MYCN-selectivity. Here, PRMT5 is linked to neuroblastoma.